A resolution designating July 15, 2023, as "National Leiomyosarcoma Awareness Day".

Whereas leiomyosarcoma is a malignant sarcoma subtype, one of 70 to 100 such subtypes, that arises in smooth muscle and has several subtypes itself due to its vascularity and bone invasion;

Whereas leiomyosarcoma is designated by the National Institutes of Health as a rare form of cancer;

Whereas leiomyosarcoma is largely resistant to standard chemotherapy treatments, radiation treatments, and immunotherapy trials, with 40-year-old chemotherapy treatments still in use;

Whereas leiomyosarcoma affects all age groups, including children, young adults, the middle-aged, and the elderly, and all genders;

Whereas leiomyosarcoma is diagnosed in more than 2,000 individuals in the United States each year;

Whereas, with respect to leiomyosarcoma, research and clinical trials remain complicated and extremely costly due to the difficulty of recruiting patients;

Whereas survival and longevity for individuals with leiomyosarcoma has not significantly improved for at least 30 years;

Whereas multidisciplinary care coordination teams, because of their expertise and experience, are critical to the health of leiomyosarcoma patients;

Whereas researchers continue to strive to improve quality of life for leiomyosarcoma patients, improve outcomes in clinical trials, and promote enhanced survivorship; and

Whereas increased education and awareness about sarcoma and leiomyosarcoma will contribute to the well-being of the communities of the United States: Now, therefore, be it